Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Primary results of the randomized trial of metformin administration in polycystic kidney disease (TAME PKD)
Ronald D. Perrone, Kaleab Z. Abebe, Terry Watnick, et al.
Kidney International (2021) Vol. 100, Iss. 3, pp. 684-696
Open Access | Times Cited: 64

Showing 1-25 of 64 citing articles:

Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype
Sarah R. Senum, Ying Li, Katherine A. Benson, et al.
The American Journal of Human Genetics (2021) Vol. 109, Iss. 1, pp. 136-156
Open Access | Times Cited: 103
KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Olivier Devuyst, Curie Ahn, Thijs R.M. Barten, et al.
Kidney International (2025) Vol. 107, Iss. 2, pp. S1-S239
Open Access | Times Cited: 4
Nutrient-sensing mTORC1 and AMPK pathways in chronic kidney diseases
Christopher Huynh, Jaewhee Ryu, Jooho Lee, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 2, pp. 102-122
Closed Access | Times Cited: 48
PGC-1α inhibits the NLRP3 inflammasome via preserving mitochondrial viability to protect kidney fibrosis
Bo Young Nam, Jong Hyun Jhee, Jimin Park, et al.
Cell Death and Disease (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 46
Autosomal Dominant Polycystic Kidney Disease: From Pathophysiology of Cystogenesis to Advances in the Treatment
Jana Reiterová, Vladimı́r Tesař
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3317-3317
Open Access | Times Cited: 39
Feasibility and impact of ketogenic dietary interventions in polycystic kidney disease: KETO-ADPKD—a randomized controlled trial
Sadrija Cukoski, Christoph Heinrich Lindemann, Sita Arjune, et al.
Cell Reports Medicine (2023) Vol. 4, Iss. 11, pp. 101283-101283
Open Access | Times Cited: 36
Metformin improves relevant disease parameters in an autosomal dominant polycystic kidney disease mouse model
Núria M. Pastor‐Soler, Hui Li, Jessica Pham, et al.
AJP Renal Physiology (2021) Vol. 322, Iss. 1, pp. F27-F41
Closed Access | Times Cited: 53
Effects of Hydrochlorothiazide and Metformin on Aquaresis and Nephroprotection by a Vasopressin V2 Receptor Antagonist in ADPKD
Bart J. Kramers, Iris W. Koorevaar, Maatje D.A. van Gastel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 4, pp. 507-517
Open Access | Times Cited: 28
Metformin for preventing the progression of chronic kidney disease
Ragada El-Damanawi, Isabelle Kitty Stanley, Christine E. Staatz, et al.
Cochrane library (2024) Vol. 2024, Iss. 6
Closed Access | Times Cited: 7
How Does ADPKD Severity Differ Between Family Members?
Klement C. Yeung, Elise Fryml, Matthew B. Lanktree
Kidney International Reports (2024) Vol. 9, Iss. 5, pp. 1198-1209
Open Access | Times Cited: 6
Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study
Godela Brosnahan, Wei Wang, Berenice Y. Gitomer, et al.
American Journal of Kidney Diseases (2021) Vol. 79, Iss. 4, pp. 518-526
Open Access | Times Cited: 40
Drugs in Clinical Development to Treat Autosomal Dominant Polycystic Kidney Disease
Thomas Bais, Ron T. Gansevoort, Esther Meijer
Drugs (2022) Vol. 82, Iss. 10, pp. 1095-1115
Open Access | Times Cited: 24
Drug repurposing in autosomal dominant polycystic kidney disease
Julie Zhou, Vicente E. Torres
Kidney International (2023) Vol. 103, Iss. 5, pp. 859-871
Open Access | Times Cited: 13
Treatment of Autosomal Dominant Polycystic Kidney Disease
Sara S. Jdiaa, Reem A. Mustafa, Alan S.L. Yu
American Journal of Kidney Diseases (2024)
Open Access | Times Cited: 5
Pathophysiology of Primary Cilia: Signaling and Proteostasis Regulation
Emanuela Senatore, Rosa Iannucci, Francesco Chiuso, et al.
Frontiers in Cell and Developmental Biology (2022) Vol. 10
Open Access | Times Cited: 20
Experimental Models of Polycystic Kidney Disease: Applications and Therapeutic Testing
Cynthia J. Sieben, Peter C. Harris
Kidney360 (2023) Vol. 4, Iss. 8, pp. 1155-1173
Open Access | Times Cited: 12
Metformin Use and Clinical Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Nationwide Cohort Study
I‐Ching Kuo, Ming‐Yen Lin, Yu–Hsiang Tsao, et al.
Biomedicines (2025) Vol. 13, Iss. 3, pp. 635-635
Open Access
A novel direct adenosine monophosphate kinase activator ameliorates disease progression in preclinical models of Autosomal Dominant Polycystic Kidney Disease
Pascale Gluais Dagorn, Bjoern Buchholz, Andre Kraus, et al.
Kidney International (2023) Vol. 103, Iss. 5, pp. 917-929
Open Access | Times Cited: 9
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
Xia Zhou, Vicente E. Torres
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 13
Autosomal Dominant Polycystic Kidney Disease Therapies on the Horizon
Julie Zhou, Vicente E. Torres
Advances in Kidney Disease and Health (2023) Vol. 30, Iss. 3, pp. 245-260
Closed Access | Times Cited: 7
From inflammation to renal fibrosis: A one-way road in autoimmunity?
Dario Roccatello, Hui Y. Lan, Savino Sciascia, et al.
Autoimmunity Reviews (2023) Vol. 23, Iss. 4, pp. 103466-103466
Closed Access | Times Cited: 7
Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights
Irene Capelli, Sarah Lerario, Francesca Ciurli, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 5, pp. 469-484
Closed Access | Times Cited: 2
Oral delivery of nanomedicine for genetic kidney disease
Yi Huang, Jonathan Wang, Valeria Mancino, et al.
PNAS Nexus (2024) Vol. 3, Iss. 5
Open Access | Times Cited: 2
Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Kitty St Pierre, Brydee Cashmore, Davide Bolignano, et al.
Cochrane library (2024) Vol. 2024, Iss. 10
Closed Access | Times Cited: 2
AMPK and Polycystic Kidney Disease Drug Development: An Interesting Off-Target Target
Michael J. Caplan
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top